Abstract: Initiation of antiretroviral therapy during acute HIV-1 infection may prevent persistent immune activation. We analyzed longitudinal CD38+HLA-DR+ CD8+ T-cell percentages in 31 acutely infected individuals who started early (median 43 days since infection) and successful antiretroviral therapy, and maintained viral suppression through 96 weeks. Pretherapy a median of 72.6% CD8+ T cells were CD38+HLA-DR+, and although this decreased to 15.6% by 96 weeks, it remained substantially higher than seronegative controls (median 8.9%, P = 0.008). Shorter time to suppression predicted lower activation at 96 weeks. These results support the hypothesis that very early events in HIV-1 pathogenesis may result in prolonged immune dysfunction.
*Department of Medicine, Center for Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC;
the Departments of †Surgery and
‡Medicine, Duke University, Durham, NC; and
§Department of Medicine, Emory University, Atlanta, GA.
Correspondence to: Michael J. Vinikoor, MD, Center for Infectious Diseases, University of North Carolina, 130 Mason Farm Road, CB #7030, 2nd Floor Bioinformatics, Chapel Hill NC 27599 (e-mail: email@example.com).
Supported by research contracts from Bristol-Myers Squibb, Gilead Sciences, and Janssen Therapeutics, and the following NIH-funded programs: UNC Center for AIDS Research (CFAR; 1P30 AI 50410-04), Duke CFAR (1P30 AI 64518), NCRR UL1TR000083, 5R01 AI050483, 5R13 AI084562, 2K24 AI01608 award, and 5T32 AI07001-35 award. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the article.
C.L.G. has received research support from Bristol-Myers Squibb, Gilead Sciences, and Janssen Therapeutics. C.B.H. has received grant support and/or consulting/honoraria from Bristol-Myers Squibb, GlaxoSmithKline/Viiv, Merck, Janssen Therapeutics, Gilead Sciences, Myriad, and Koronis. D.M.M. has received research support from Bristol-Myers Squibb, Gilead Sciences, and Merck, and honoraria from Bristol-Myers Squibb, Merck, Chimerix, and Janssen Therapeutics. J.J.E. receives research support from Bristol-Myers Squibb and GlaxoSmithKline and is a consultant to Bristol-Myers Squibb, Merck, GlaxoSmithKline/ViiV Healthcare, and Janssen Therapeutics. M.J.V., A.C., G.F., K.S.M., J.D.K., and J.L.L. have no conflicts of interest to disclose.
Received September 20, 2012
Accepted January 02, 2013
Interventions during acute HIV infection (AHI) may present a unique opportunity to alter the pathogenesis of the disease. In the natural history of HIV infection, early and complex virus–host interactions lead to chronic depletion and hyperactivation of T cells.1 Within weeks of HIV acquisition, the host innate immune system responds with a cytokine storm that likely produces the symptoms of acute retroviral syndrome (ARS).1–3 CD4+ and CD8+ cells become activated. But for rare individuals, host immune responses reduce but fail to fully suppress viremia. During acute infection and in the absence of treatment, CD8+ cell activation reaches a steady state.4 Although the mechanisms by which immune activation contributes to immunodeficiency are not fully understood, an individual's level of CD8+ cell activation independently predicts the rate at which HIV disease progresses.5
Antiretroviral therapy (ART) reduces mortality in HIV-infected individuals through virologic suppression (VS), reconstitution of CD4+ cells, and reduction of T-cell activation. Although ART reduces T-cell activation, many persons with treated and suppressed chronic HIV infection (CHI) have persistently elevated levels of activation.6,7 Persistent activation may slow down the reconstitution of CD4+ cells and increase mortality from both AIDS and non-AIDS events.6 Although the phenomenon of persistent immune activation is primarily described after CHI, the activation outcomes of acutely infected and treated individuals are not well described.
Although effective,8 the personal health benefits of starting ART during AHI are unproven.9,10 A short course of ART started during AHI reduces the symptoms of ARS and may decrease the rate of CD4+ cell count decline after ART discontinuation.11 In addition, ART provided during AHI may reduce the viral set point.12,13 Although the possible benefits of providing a short course of ART during AHI have been investigated, the impact of long-term ART begun early after infection on immune activation is unknown.
In this study, we analyzed the longitudinal dynamics of CD8+ cell activation in acutely infected adults treated with ART. We selected patients with the best possible treatment outcomes (those who started immediate ART, achieved VS, and at 96 weeks remained suppressed) to determine the efficacy of ART in preventing chronic persistent immune activation. We compared the CD8+ cell activation levels of AHI patients with seronegative controls, and determined whether the timing of ART initiation or rapidity of VS was associated with the levels of activation in the setting of effectively treated HIV-1.
Adults diagnosed with AHI and linked to care at the University of North Carolina at Chapel Hill, Duke University, or Emory University were enrolled in an open-label, nonnucleoside reverse transcriptase inhibitor– or protease inhibitor–based ART treatment trial within 45 days of AHI diagnosis. We defined AHI by a negative or indeterminate enzyme immunoassay (EIA) or a negative HIV RNA test within 45 days of enrollment plus reproducibly detectable HIV RNA by amplification methods. All the participants had blood sent for baseline HIV genotyping before ART initiation. We included only patients who achieved VS (HIV RNA ≤200 copies per millliter) by 48 weeks and sustained suppression through 96 weeks. Patients were excluded if CD8+ activation was not measured pretreatment and then serially through 96 weeks (±12 weeks).
At enrollment, ARS symptoms were recorded as previously described.8,14 We estimated the date of HIV infection as 14 days before the onset of symptoms consistent with ARS.3,15 The time (in days) from the estimated date of infection to AHI diagnosis and to ART initiation was calculated. Sexually transmitted infections (STIs) in the 8 weeks preceding HIV diagnosis were recorded.
Before ART and at weeks 12, 24, 48, 72, and 96 after therapy initiation, the HIV RNA level and the percent of CD8+ cells expressing CD38 and HLA-DR were measured. HIV RNA was quantified using the Roche Amplicor Monitor ultrasensitive assay or the Abbott Real-Time HIV-1 assay. The percent of CD38+HLA-DR+ CD8+ cells was measured on fresh blood samples collected in EDTA tubes. Activated CD8+ cells were identified using the following antibodies: αCD3-PerCP, αCD8 fluorescein isothiocyanate, αHLA-DR-APC, and αCD38-PE. Antibody staining was evaluated using a 4-color Calibur flow cytometer instrument (Becton Dickinson, San Jose, CA). In the same laboratory, 30 HIV-seronegative volunteers (70% women and median age 32 years) provided fresh blood samples for measurement of CD8+ cell activation using the same methods. Beyond age and gender, the clinical characteristics of seronegative volunteers were not available. We defined normal CD8+ activation as less than or equal to the 95th percentile of the seronegative cohort's distribution of activation levels.
The Pearson χ2 test was used for bivariable analyses between categorical baseline characteristics and immune activation. The Wilcoxon rank-sum test was used to compare the percent activation between acutely HIV-infected and seronegative participants and for continuous pretherapy characteristics of the AHI cohort. We calculated the proportion of AHI patients whose T-cell activation normalized by 96 weeks. Using multivariable linear regression with generalized estimating equations, we determined the impact of the timing of ART initiation and the rapidity of VS on immune activation. SAS version 9.2 (Cary, NC) and Stata 11 (College Station, TX) were used for analyses. The study was approved by the University of North Carolina at Chapel Hill and Duke Institutional Review Boards. All the participants provided written informed consent.
Of 138 adults with AHI who initiated ART within 45 days of diagnosis since 1998, 31 met the criteria for analysis. We excluded 14 AHI patients without sustained suppression for 96 weeks, 67 without CD8+ activation markers measured longitudinally, and 26 who had not yet reached 96 weeks. Baseline demographic, virologic, and immunologic characteristics were similar between those included and excluded from the analysis (data not shown). Median age at therapy initiation was 32 years (range 19–64) and 29 patients (94%) were men (Table 1). At diagnosis, 97% reported at least 1 (median 6) ARS-associated symptom. One participant reported no symptoms of AHI, and therefore, his estimated date of infection was not determined. In the 8 weeks preceding AHI diagnosis, 3 (10%) participants had a documented STI (genital herpes, chlamydia, or nongonococcal urethritis).
At AHI diagnosis, 16 (52%) participants tested EIA negative, 9 (29%) tested EIA positive but western blot (WB) negative or indeterminate, and 6 (20%) tested EIA and WB positive with a negative or indeterminate test in the previous 30 days. Each patient had at least 2 pre-ART viral loads. The median observed peak HIV RNA level was 5.86 log10 copies per milliliter [interquartile range (IQR) 5.49–6.15]. By the date of therapy initiation, the median HIV RNA level had decreased to 5.27 log10 copies per milliliter (IQR 4.50–5.77). The median CD4+ cell count nadir was 392 cells per cubic millimeter, and 5 (16%) participants had a nadir CD4+ cell count <200 cells per cubic millimeter.
The median time from acquisition to AHI diagnosis was 25 days (IQR 19–31) and from acquisition to ART initiation was 43 days (IQR 39–53). In this cohort, 28 (90%) patients received nonnucleoside reverse transcriptase inhibitor–based regimens (coformulated emtricitabine, tenofovir, and efavirenz or coformulated emtricitabine and tenofovir plus nevirapine), 1 patient received a protease inhibitor–based regimen (stavudine, didanosine, and nelfinavir), and for 2 participants the regimen type was missing. We were not able to compare the effect of regimen type on immune activation. Three patients (10%) had transmitted drug resistance, but only 1 patient required a change of therapy. The median time to VS was 12 weeks (IQR 8–17).
Pretherapy, the median percent CD38+HLA-DR+ CD8+ cells was 72.6 (IQR 22.6–92.6). CD8+ activation decreased substantially from baseline to week 12 and then more slowly during subsequent measurements (Fig. 1). From weeks 48–96, the median activation of ART-treated AHI patients decreased by 3.8% (P = 0.07). However, at 96 weeks, the median percent CD38+HLA-DR+ CD8+ cells remained higher in participants with ART-treated AHI versus the seronegative controls [15.6 (IQR 11.1–22.6) versus 8.9 (IQR 5.8–14), P < 0.01]. Approximately 40% of AHI patients failed to reach normal levels of activation by 96 weeks (Fig. 1).
In bivariable analyses, log10 peak viral load, pretreatment CD8+ cell activation, and time to VS were associated with CD8+ activation at 96 weeks (all P < 0.05). Among both the AHI patients and seronegative controls, we did not find an association between age or gender and CD8+ activation. Recent STI diagnosis among AHI patients was also not associated with higher levels of immune activation. In multivariable analyses, shorter time from estimated date of infection to ART initiation was not associated with a reduction in CD8+ activation at 96 weeks (P = 0.6). However, after adjustment for age, CD4+ cell nadir, and peak viral load, shorter time to VS predicted a reduction of CD8+ activation at 96 weeks (P = 0.002). For every 1-month decrease in time to VS, CD8+ activation at 96 weeks decreased by 0.85%.
As part of a recently published study,16 4 (13%) participants also underwent measurements of the size of the viral reservoir (at mean 92 weeks of ART). There was a positive but nonsignificant correlation between the log10-transformed frequency of latently infected cells (reservoir size) and CD8+ activation at 96 weeks (Spearman ρ = 0.8, P = 0.2), and a correlation between frequency of latently infected cells and low-level plasma viremia as measured by a single-copy assay.16
Among 31 acutely HIV-infected patients with rapid linkage to care, early initiation of ART, and rapid and durable VS, CD8+ activation decreased substantially during the first 12 weeks of therapy and then decreased more slowly with increased duration of VS. Despite 2 years of suppressive ART, AHI patients had a higher CD8+ activation compared with seronegative controls, with 40% failing to reach normal levels. Although not fully understood, immune activation seems to play a central role in HIV pathogenesis,17 and this study builds on the existing evidence in CHI that immune activation persists in many patients.6,7
Data from this study add to a discordant story regarding the immunologic benefits of starting ART during acute/early infection.4 During 1 ART interruption trial, patients who started ART during acute versus early HIV infection had no difference in activated CD8+ cells at 48 weeks.18 However, more recently patients who started ART earlier (median 75 days of infection) had lower levels of CD8+ cell activation versus those who started later (median 3.1 years).19 We found no association between the timing of ART initiation and CD8+ activation, possibly due to the narrow range (21–67 days) of time to treatment within our cohort. Further, as CD8+ activation levels may vary depending on laboratory technique and whether fresh or previously frozen cells are used, our results on fresh cells are not directly comparable with other cohorts of patients receiving ART. Unfortunately, a direct comparison of CD8+ activation between acute and chronically infected patients at our center, which would have strengthened our findings, was not feasible.
One possible explanation for persistence of immune activation is the extensive and rapid depletion of gut associated lymphoid tissue, which may result in a state of chronic hyperactivation and inadequate immune restoration.20,21 Persistently elevated levels of activated lymphocytes were found in the GI tract 3–7 years after suppressive ART was initiated during acute or early infection even while peripheral blood activation markers normalized.22 In our study, although only 60% of patients by 96 weeks had reached a level within the range of uninfected subjects, activation decreased with increased duration of VS (Fig. 1). This observation suggests that with time, further normalization of peripheral blood activation markers may occur. However, peripheral blood lymphocytes represent only a tiny fraction of all lymphocytes and gut associated lymphoid tissue may be a better (but more logistically challenging) site for examination of the overall immunological status of HIV-infected individuals.
Although median levels of CD8+ activation remained higher than in controls, we found that more rapid VS predicted reduced immune activation. Despite the very high viral load seen during AHI, the time to VS during ART may actually be shorter than seen with CHI.8 Time under the viremia curve in the setting of AHI has been shown to correlate with the size of the viral reservoir in resting CD4+ cells.16 A correlation between the frequency of latently infected cells and low-level plasma viremia as measured by a single-copy assay was also reported.16 Release of virus from this reservoir may produce low-level viremia and immune activation.23 Therefore, limiting the reservoir size could reduce CD8+ activation. The correlation we identified, in 4 patients, between reservoir size and immune activation did not reach statistical significance. These preliminary observations deserve future study, and we suggest that therapy that rapidly suppresses viremia should be further examined in the setting of AHI.
The goal of this analysis was to investigate those individuals who had an optimal response to ART, in effect to evaluate a “best-case” scenario. Therefore, our cohort may not be representative of all AHI patients (due to our selection for durable VS). In addition, we had limited knowledge regarding the health of seronegative controls. The control group consisted of employees at a University hospital. Beyond age and gender, we unfortunately had no additional information regarding their medical histories. Proinflammatory coinfections (such as hepatitis B/C, CMV, and/or STIs) may have been less common among controls and could have produced the difference in CD8+ activation seen between ART-treated AHI patients and seronegative controls.
In the early stages of HIV infection, virus–host interactions result in steady states of HIV RNA and CD8+ activation. These parameters determine the rate at which HIV progresses and may be associated with the risk of death from non-AIDS-associated conditions.24 In this study, we found that initiation of ART during acute HIV-1 infection failed to prevent the persistence of immune activation at 96 weeks of suppressive therapy. These results suggest that the early pathogenesis of HIV disease leaves a long-lasting imprint on host immune function.
1. Cohen MS, Shaw GM, McMichael AJ, et al.. Acute HIV-1 infection. N Engl J Med. 2011;364:1943–1954.
2. Stacey AR, Norris PJ, Qin L, et al.. Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections. J Virol. 2009;83:3719–3733.
3. Gay C, Dibben O, Anderson JA, et al.. Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS One. 2011;6:e19617.
4. Deeks SG, Kitchen CMR, Liu L, et al.. Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. Blood. 2004;104:942–947.
5. Fahey JL, Taylor JMG, Manna B, et al.. Prognostic significance of plasma markers of immune activation, HIV viral load and CD4 T-cell measurements. AIDS. 1998;12:1581–1590.
6. Hunt PW, Martin JN, Sinclair E, et al.. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus–infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534–1543.
7. Robbins GK, Spritzler JG, Chan ES, et al.. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis. 2009;48:350–361.
8. Gay CL, Mayo AJ, Mfalila CK, et al.. Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. AIDS. 2011;25:941–949.
9. Bell SK, Little SJ, Rosenberg ES. Clinical management of acute HIV infection: best practice remains unknown. J Infect Dis. 2010;202:S278–S288.
10. O'Brien M, Markowitz M. Should we treat acute HIV infection? Curr HIV/AIDS Rep. 2012;9:101–110.
11. Fidler S, Fox J, Touloumi G, et al.. Slower CD4 cell decline following cessation of a 3 month course of HAART in primary HIV infection: findings from an observational cohort. AIDS. 2007;21:1283–1291.
12. Hecht FM, Wang L, Collier A, et al.. A multicenter observational study of the potential benefits of initiating combination antiretroviral therapy during acute HIV infection. J Infect Dis. 2006;194:725–733.
13. Von Wyl V, Gianella S, Fischer M, et al.. Early antiretroviral therapy during primary HIV-1 infection results in a transient reduction of the viral setpoint upon treatment interruption. PLoS One. 2011;6:e27463.
14. McKellar MS, Cope AB, Gay CL, et al.. Acute HIV infection in the southeastern United States: a cohort study. AIDS Res Hum Retroviruses. 2013;29:121–128.
15. Linback S, Thorstensson R, Karlsson AC, et al.. Diagnosis of primary HIV-1 infection and duration of follow-up after HIV exposure. AIDS. 2000;14:2333–2339.
16. Archin NM, Vaidya NK, Kuruc JD, et al.. Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci. 2012;109:9523–9528.
17. Hunt PW. Role of immune activation in HIV pathogenesis. Curr HIV/AIDS Rep. 2007;4:42–47.
18. Volberding P, Demeter L, Bosch RJ, et al.. Antiretroviral therapy in acute and recent HIV infection: a prospective multicenter stratified trial of intentionally interrupted treatment. AIDS. 2009;23:1987–1995.
19. Jain V, Hartogensis W, Bacchetti P, et al.. ART initiation during acute/early HIV infection compared to later ART initiation is associated with improved immunologic and virologic parameters during suppressive ART [abstract #517]. Paper presented at: 18th Conference on Retroviruses and Opportunistic Infections; 2011; Boston, MA.
20. Estes J, Baker JV, Brenchley JM, et al.. Collagen deposition limits immune reconstitution in the gut. J Infect Dis. 2008;198:456–464.
21. Jiang W, Lederman MM, Hunt P, et al.. Plasma levels of bacterial DNA correlate with immune activation and the magnitude of immune restoration in persons with antiretroviral-treated HIV infection. J Infect Dis. 2009;199:1177–1185.
22. Mehandru S, Poles MA, Tenner-Racz K, et al.. Lack of mucosal immune reconstitution during prolonged treatment of acute and early HIV-1 infection. PLoS Med. 2006;3:e484.
23. Mavigner M, Delobel P, Cazabat M, et al.. HIV-1 residual viremia correlates with persistent T-cell activation in poor immunological responders to combination antiretroviral therapy. PLoS One. 2009;4:e7658.
24. Hunt PW, Rodriguez B, Shive C, et al.. Gut epithelial barrier dysfunction, inflammation, and coagulation predict higher mortality during treated HIV/AIDS [abstract #278]. Paper presented at: 19th Conference on Retroviruses and Opportunistic Infections; 2012; Seattle, WA.